One in vitro experiment demonstrated that IFN-γ could protect ovarian carcinoma cell lines from CTL-mediated lysis by upregulating HLA-E on cancer cells, which engaged the inhibitory CD94/NKG2A receptor on CD8+ effector T cells (18). The gene discussed is IFNG; the disease is ovarian carcinoma.